Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often concomitantly with epidermal growth factor receptor (EGFR), including H1975 cell line. The erlotinib-resistant lung cancer cell line H1975, which expresses L858R/T790M-EGFR in-cis, was used to test for the effect of MET inhibition using the small molecule inhibitor SU11274. H1975 cells express wild-type MET, without genomic amplification (CNV ¼ 1.1). At 2 mM, SU11274 had significant in vitro pro-apoptotic effect in H1975 cells, 3.9-fold (P ¼ 0.0015) higher than erlotinib, but had no effect on the MET and EGFR-negative H520 cells. In vivo, SU11274 also induced significant tumour cytoreduction in H1975 murine xenografts in our bioluminescence molecular imaging assay. Using small-animal microPET/MRI, SU11274 treatment was found to induce an early tumour metabolic response in H1975 tumour xenografts. MET and EGFR pathways were found to exhibit collaborative signalling with receptor cross-activation, which had different patterns between wild type (A549) and L858R/ T790M-EGFR (H1975). SU11274 plus erlotinib/CL-387,785 potentiated MET inhibition of downstream cell proliferative survival signalling. Knockdown studies in H1975 cells using siRNA against MET alone, EGFR alone, or both, confirmed the enhanced downstream inhibition with dual MET -EGFR signal path inhibition. Finally, in our time-lapse video-microscopy and in vivo multimodal molecular imaging studies, dual SU11274-erlotinib concurrent treatment effectively inhibited H1975 cells with enhanced abrogation of cytoskeletal functions and complete regression of the xenograft growth. Together, our results suggest that MET-based targeted inhibition using small-molecule MET inhibitor can be a potential treatment strategy for T790M-EGFR-mediated erlotinib-resistant non-small-cell lung cancer. Furthermore, optimised inhibition may be further achieved with MET inhibition in combination with erlotinib or an irreversible EGFR-TKI.
Receptor tyrosine kinases (RTKs) play a key role in lung cancer tumorigenesis and progression (Choong et al, 2005) . Progress has been made in the treatment of advanced non-small-cell lung cancer (NSCLC) using small-molecule tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, targeting epidermal growth factor receptor (EGFR) (Lynch et al, 2006) . EGFR kinase domain mutations (frequently L858R) and exon 19 deletions have been identified to be predictive of response to gefitinib/erlotinib (Shigematsu and Gazdar, 2006; Sharma et al, 2007) . Although erlotinib was shown to prolong survival in a large phase III randomised trial (NCIC-BR.21) (Shepherd et al, 2005) , the majority of unselected lung cancer patients are still primary nonresponders. Patients whose cancer has wild-type EGFR genotype are generally non-responders but may at best derive stable disease from the TKIs. Initial responders with mutant EGFR invariably develop secondary resistance and soon succumb to the disease. At least half of the acquired resistance is mediated by the 'gatekeeper' mutation T790M-EGFR (Kobayashi et al, 2005a; Pao et al, 2005) . Moreover, T790M was found in the H1975 cell line, in combination with L858R, which was previously established without prior exposure to EGFR TKIs. Hence, T790M may also have a role in primary EGFR-TKI resistance. Currently, there are still no Federal Drug Administration (FDA)-approved clinical inhibitors that can overcome T790M-mediated EGFR-TKI resistance yet.
The MET receptor has been shown to be an important molecule in a variety of malignancies (Tsarfaty et al, 1994; Schmidt et al, 1997 Schmidt et al, , 1998 Schmidt et al, , 1999 Birchmeier et al, 2003; Ma et al, 2003b; Benvenuti and Comoglio, 2007) , and has recently been validated as an attractive therapeutic target in cancer therapy, including lung cancer (Ma et al, 2003a (Ma et al, , 2005a Christensen et al, 2005; Salgia, 2006) . Overexpression of MET or its ligand HGF have been found to confer a poor prognosis (Ma et al, 2003b; Miyata et al, 2006; Garcia et al, 2007; Sawada et al, 2007) . Dysregulation of the MET-HGF signalling axis upregulates diverse tumour cell functions, including cell proliferation, survival, cell scattering and motility, epithelial-mesenchymal transition, angiogenesis, invasion, and metastasis (Corso et al, 2005; Dietrich et al, 2005; Ma et al, 2005a; Peruzzi and Bottaro, 2006) . Reversible small-molecule inhibitors such as SU11274 targeting MET have been developed for therapeutic inhibition Sattler et al, 2003; Ma et al, 2005a, b) . We hypothesised that MET signalling plays a key role in lung cancer oncogenic signalling and optimised therapy targeting MET would be effective as a treatment strategy in the face of EGFR-TKI resistance. In this study, we sought to define the role of MET signalling in EGFR-TKI-resistant lung cancer. Furthermore, using a combination of small-molecule kinase inhibitors and short-interfering RNA (siRNA), we examined the role of MET inhibition, either alone or combined with EGFR inhibition, using both in vitro and in vivo assays against the EGFR-TKI-resistant lung cancer cell line H1975 (L858R/T790M-mutant EGFR). Our data support the potential role of dual TKI combinatorial inhibition using EGFR inhibitors to enhance MET inhibition in T790M-EGFR-mediated therapy resistance.
MATERIALS AND METHODS

Cell culture, cell lysates preparation, immunoprecipitation, and immunoblotting
Lung cancer cell lines were obtained from American Type Culture Collection and grown in RPMI 1640 (Hyclone, Logan, UT, USA), 10% (v/v) foetal bovine serum (FBS) as instructed under standard cell culture conditions. For growth factor stimulation studies, human HGF (50 ng ml À1 ) (R&D Systems, Minneapolis, MN, USA) and human EGF (100 ng ml À1 ) (Calbiochem, Cambridge, MA, USA) were used as indicated. Cellular proteins were extracted from whole cells as previously described (Choong et al, 2006) . Immunoprecipitation (IP) studies and immunoblotting (WB) were performed as previously described (Maulik et al, 2002; Choong et al, 2006) (Ma et al, 2005a) and CL-387,785 were purchased from EMD-Calbiochem (Cambridge, MA, USA), dissolved in DMSO, and used at the indicated concentrations. Erlotinib was prepared as previously described (Choong et al, 2006) .
Genomic studies of MET gene DNA extraction and DNA sequencing: Genomic DNA of H1975 cells were extracted using Qiagen DNAeasy Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Direct DNA sequencing of the complete MET gene was performed as previously described (Ma et al, 2005a) .
Quantitative real-time polymerase chain reaction (QPCR): Genomic copy number variation of the MET gene was determined in triplicate using QPCR with the RNaseP as the reference gene. Quantitative realtime polymerase chain reactions were performed in ABI PRISM 7900-HT System and the reaction conditions are available upon request. The QPCR primers for MET copy number variation determination were purchased from ABI (ABI assay no.: Hs01565582_g1).
Cellular apoptosis and viability assay: For cellular apoptosis assays, cells were plated separately in triplicate in six-well plates in 10% FBS-containing media. Drug inhibitor treatment using erlotinib, SU11274, or DMSO control as indicated was added the next day, with the cells incubated for 72 h further. Cellular apoptosis was determined by fluorescence-activated cell sorting (FACS) analysis using the Annexin-V-Fluos Staining Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Cellular apoptosis assays were performed in triplicate. Cellular viability assays were performed using the Trypan-Blue Dye Exclusion assay with duplicate counting using standard haemacytometer-light microscopy, with each experiment further repeated in duplicate.
Time-lapsed video microscopy and image analysis of cytoskeletal functions H1975 cells were plated on cell culture dishes and placed into a temperature-controlled chamber at 371C in an atmosphere of 5% CO 2 . The cells were examined by and recorded under video microscopy using an Leica 6000 B inverted microscope, Pecon incubation chamber, and Retiga EXI 12 bit camera (Q imaging, Vancouver, BC, Canada) with MetaMorph image analysis software (Universal Imaging, Downington, PA, USA) (details see also Supplementary Materials and Methods).
Lentivirus transduction of luciferase-expressing vector (a) Lentivirus production: Plasmids. The packaging plasmid pCMVÄ R8.91, the vesicular stomatitis virus glycoprotein G (VSV.G), and encoding plasmid pCSO-rre-cppt-MCU3-LUC were kind gifts from Dr Donald B Kohn (University of Southern California). Virus production. Transfection with transfer vector, packaging plasmid and envelope plasmid were performed by calcium phosphate precipitate 12 h after planting package 293T cells into 10 cm cell culture dishes. (b) Lentiviral transduction of EGFR-TKI-resistant lung tumour cells: Medium from the package cell culture was then collected and centrifuged at 3000 r.p.m. for 5 min at room temperature, followed by filtering through 0.45 mm filter. The filtered medium containing virus particles was then added to the target transduction cells (H1975), which were plated the day before transduction.
In vivo murine xenograft model
Six-week-old female Ncr-nu (Nude) mice were purchased from Charles River Laboratories (Wilmington, MA, USA) and hosted in the pathogen-free animal facility at the Case Western Reserve University. In vivo animal studies were performed according to institution-approved protocols and guidelines. Xenografts of the luciferase-expressing H1975 lung cancer cells were established by intradermally injecting 3 Â 10 6 viable cells in RPMI 1640 media into the flank/leg region of nude mice to produce subcutaneous tumours. Indicated treatments with targeted TKIs were given at the time when tumour xenografts were beginning to be visible (corresponding to 7 days post-implantation of H1975 cells). In vivo daily inhibitor drug treatments were performed as indicated. SU11274 was administered as intratumoral injections, whereas erlotinib was administered using oral gavage. Body weight was recorded for each animal twice weekly to monitor potential toxicities. Tumour xenografts were subsequently dissected and harvested at the end of the experiments, formalin-fixed, and stained with haematoxylin and eosin (H&E) using standard techniques.
Small animal in vivo imaging (a) Bioluminescence imaging (BLI): Xenograft tumour growth of H1975-luc cells were monitored by non-invasive luciferase-bioluminescence molecular imaging. Mice were imaged by BLI using a Xenogen IVIS s 200 bioluminescence scanner (Xenogen, Hopkinton, MA, USA) at indicated times on the pretreatment day as baseline, and then on various post-TKI treatment days as specified (details see also Supplementary Materials and Methods). (b) MicroPET/magnetic resonance imaging (MRI) imaging: For microPET/MRI imaging study, H1975 tumour xenografts were allowed to grow to a readily visible size in a total of 7 days post-implantation to ensure adequate baseline micro-PET uptake. H1975 tumour xenografts were treated with (a) diluent control and (b) SU11274 (100 mg per xenograft). The nude mice were subjected to MRI (Bruker Biospec 7T MRI scanner, Bruker BioSpin MRI, Billerica, MA, USA) and microPET scanning (R4 micro-PET system, Siemens Medical Solutions, Knoxville, TN, USA) at the indicated time of treatment (details see also Supplementary Materials and Methods).
siRNA inhibition
Specific siRNAs targeting human MET or EGFR mRNA, ON-TARGET plus SMARTpool, were purchased from Dharmacon Inc. (Chicago, IL, USA). The siRNA duplexes were transiently transfected using DharmaFECT 1 Transfection reagent (Dharmacon Inc.) according to the manufacturer's instructions. Control transfection using scrambled siRNA was performed in parallel using ON-TARGETplus siCONTROL siRNA (Dharmacon Inc.).
Statistical analysis
Statistical significance was tested by two-tailed Student's t-test, with P-value of less than 0.05 considered statistically significant.
RESULTS
Co-expression of MET and EGFR in lung cancer
We first examined the expression pattern of MET and EGFR in lung cancer cell lines. Nine of 11 NSCLC cell lines (82%) (except H520 and H661) (see Supplementary Table 1 for baseline characteristics of the cell lines) co-expressed both MET and EGFR, including the H1975 cell line (Figure 1 ). Signal transducer and activator of transcription 3 (STAT3) is a common downstream signalling target for both MET and EGFR, and has been shown to be crucial in mediating the oncogenic potential of mutant EGFR signalling (Song et al, 2003) . STAT3 was ubiquitously expressed in all the cell lines examined.
SU11274 induces apoptosis and inhibition of cytoskeletal functions in erlotinib-resistant H1975 lung cancer cells expressing L858R/T790M-EGFR As we found that many NSCLC cell lines co-express EGFR and MET, including H1975 cells, we first investigated if MET inhibition using the small-molecule inhibitor SU11274 can be effective in the erlotinib-resistant H1975 cells. H1975 cell line was chosen because it expresses the 'gatekeeper'-resistant T790M-EGFR mutation (in-cis with L858R) in the receptor kinase domain hydrophobic pocket, representing a major mechanism of resistance to reversible EGFR-TKI (erlotinib/gefitinib) (Kobayashi et al, 2005a; Pao et al, 2005) . SU11274 was previously characterised as a reversible inhibitor of MET, inhibiting specific tyrosine phosphorylation of the juxtamembrane CBL-binding phosphosite (pY1003), the major kinase autophosphorylation sites (pY1234/1235), as well as downstream signalling (Sattler et al, 2003; Ma et al, 2005a) . It exhibits 460-fold selectivity for MET over FLK and 4400-fold selectivity over RON, FGFR-1, SRC, CDK2, PDGFR-b, EGFR, and Tie-2 (Ma et al, 2005a ). Here, we tested the pro-apoptotic effect of SU11274 treatment, in comparison to erlotinib, in the EGFR-TKI-resistant cell line H1975 (L858R/T790M-EGFR, wild-type KRAS). SU11274 at 2 mM induced apoptosis (Annexin V-and propidium iodide-stained positive cells) in 14.8±2.4% of T790M-EGFR expressing H1975 cells, which is 5.5-fold (Po0.001) higher than diluent control and 3.9-fold (P ¼ 0.0015) higher than erlotinib. To further demonstrate that the pro-apoptotic effect of SU11274 seen above was not a result of off-target effects, we also tested the EGFR-negative and MET-negative H520 cell line as negative control. SU11274 at 5 mM did not result in any significant apoptosis in H520 cells (0.44±0.30%, P ¼ 0.22). Similarly, H520 cells were also insensitive to erlotinib without any significant apoptosis induced by the drug (0.3 ± 0.1%, P ¼ 0.35) (Figure 2 ).
SU11274 induces cytoreduction of erlotinib-resistant H1975 tumour xenograft in vivo
To further test the role of MET inhibition in EGFR-TKI-resistant lung cancer in vivo, we developed stable luciferase-expressing H1975 lung cancer cells using lentivirus transduction. These cells were used in an in vivo xenograft model coupled with multimodal molecular imaging for non-invasive monitoring of xenograft growth and tumour response to TKI. Daily treatment with the MET inhibitor SU11274 caused statistically significant interval retardation of the xenograft tumour growth of H1975 cells with a ninefold reduction (P ¼ 0.0251) in the xenograft growth, when compared with the diluent control, during the treatment period ( Figure 3A -a,b) . At the end of treatment period, SU11274-treated H1975 xenograft tumour BLI flux remained essentially unchanged at 104% (P ¼ 0.0251), when compared to 905% as seen in the diluent control ( Figure 3A 
MET -EGFR signalling cross-activation in lung cancer
As MET and EGFR often co-express in lung cancer cells (Figure 1 ), we asked if there is signalling cross-activation between MET and EGFR pathways. Both A549 (wild-type EGFR) and H1975 (L858R/T790M-EGFR) cell lines were used as models for the signalling studies ( Figure 4 ). Here, MET and EGFR signal transduction pathways were both shown to be functional and ligand-sensitive, although H1975 cells have higher serumindependent constitutively activated MET and EGFR. Enhanced and more durable downstream signalling activation was observed in phospho-AKT (survival), phospho-ERK1/2 (proliferation-differentiation), and phospho-STAT3 (transcriptional activation) when A549 and H1975 cells were co-stimulated with dual-ligand (HGF and EGF) ( Figure 4A ; see lanes 4, 7, 11, and 14) . Immunoprecipitation studies of the MET and EGFR under single-or dual-ligand stimulation confirmed the presence of receptor cross-activation between MET and EGFR in these lung cancer cell lines ( Figure 4B ). In A549 cells, HGF was capable of activating EGFR in the presence of EGF, whereas in H1975, EGF activated MET with and without co-stimulation with HGF.
MET is activated with no genomic amplification or mutations in H1975 lung adenocarcinoma cells 
Figure 2 MET inhibition with SU11274 in EGFR-TKI-resistant H1975 lung cancer cells: induction of apoptosis in vitro and inhibition of cytoskeletal functions. The MET kinase inhibitor SU11274 was used to treat H1975 cells (L858R/T790M-EGFR, wild-type KRAS) and H520 cells (negative expression for both EGFR and MET) as control. The effect of SU11274 was examined using Annexin-V/propidium iodide (PI)-FITC cellular apoptosis assay. Untreated diluent control (U) and erlotinib were included in the experiment as treatment controls for comparison. Erlotinib (EGFR inhibition) was ineffective in promoting apoptosis in any of these above cell lines at 72 h. On the other hand, MET inhibition by SU11274 at 2 mM induced significant cellular apoptosis in the EGFR-TKI-resistant H1975 cells (14.8 ± 2.4%, P ¼ 0.0015), when compared with erlotinib (3.8 ± 0.7%). For the EGFR-negative and MET-negative H520 cells, neither SU11274 (0.44 ± 0.30%, P ¼ 0.22) nor erlotinib (0.28 ± 0.13%, P ¼ 0.35) at 5 mM induced any significant cellular apoptosis when compared with diluent control (0.18 ± 0.10%). Mean values of percent cells in early apoptosis (Annexin-V plus PI staining) from three independent experiments for each of the treatment conditions were plotted in the graphs shown here. Error bar, s.e.m. (N ¼ 3).
H1975, H441, H520, H596, and H661. None of the cell lines examined exhibited MET genomic amplification. MET genomic copy number in H1975 was found to be 1.1, whereas that of A549 being 1.0 for comparison ( Figure 4B ). Direct DNA sequencing of the MET gene in H1975 did not reveal any non-synonymous mutations.
Dual inhibition with SU11274 plus erlotinib/CL-387,785 potentiates the MET-targeted inhibitory efficacy in erlotinib-resistant lung cancer cells tested against SU11274 inhibition, either alone or in combination with erlotinib. We determined the functional effect of combined MET -EGFR inhibition on the cytoskeletal functions of H1975 cells. Cell motility and migration are crucial cellular regulatory functions in tumour cell invasion and metastasis. Video microscopy studies showed that SU11274 inhibition substantially abrogated the constitutively activated cytoskeletal changes of the serum-starved H1975 cells (with activated p-MET and p-EGFR), as reflected in the cellular migrational trajectories and velocity (Supplementary Figure 3) . Moreover, SU11274 alone had some inhibitory effect on cytoskeletal functions in H1975 cells under serum-stimulated (10% FBS) conditions, whereas concurrent dual TKI combinatorial inhibition using SU11274 plus erlotinib completely abrogated the cytoskeletal functions ( Figure 5A ). Using dual-ligand concurrent stimulation (HGF and EGF) to activate both MET and EGFR in A549 and H1975 cells, single TKI alone was relatively ineffective in inhibiting the downstream signalling completely ( Figure 5B ). On the other hand, concurrent dual inhibition with MET -EGFR TKIs (SU11274 plus erlotinib) effectively induced cooperative and enhanced inhibition of the key downstream proliferative/survival and anti-apoptotic signal paths (phospho-AKT, phospho-ERK1/2, and phospho-STAT3) ( Figure 5B ). Most interestingly, despite the fact that p-EGFR[Y1068] was not significantly inhibited under the dual SU11274/erlotinib combinatorial treatment in H1975 cells, p-ERBB3[Y1289] activation was effectively abrogated only under this dual inhibitory strategy ( Figure 5B ).
The signalling experiment using MET-specific siRNA instead of SU11274 in A549 cells ( Figure 5C ) showed similar inhibition synergism using dual RTK inhibition with siRNA-MET and erlotinib. Using the A549 cell line as a model, we further demonstrated that alternative ligand-stimulated RTK signalling (MET -HGF and EGFR -EGF) indeed could rescue the downstream signalling activation from single targeted inhibitor ( Figure 5D ), supporting our hypothesis of the optimal efficacy of dual MET -EGFR inhibition especially in the in vivo setting where both RTK signal paths are functional and activated. Irreversible EGFR-TKIs (Kobayashi et al, 2005b) , such as CL-387,785 or HKI-272 (Ruhe et al, 2007) , have been shown to exhibit inhibitory efficacy against erlotinib-resistant T790M mutation. Here, in H1975 cells, results similar to erlotinib were obtained using the irreversible EGFR-TKI, CL-387,785, in combination with SU11274 ( Figure 5E ).
As erlotinib is the only FDA-approved clinical EGFR-targeted inhibitor for the treatment of advanced lung cancer in the United States, we further investigated its potential use in combination with MET inhibition against erlotinib-resistant H1975 cells using an in vitro cellular viability assay and BLI tumour xenograft growth assay in vivo. Under serum-stimulated conditions, when both EGFR and MET were basally activated, SU11274 plus erlotinib (3 mM of each TKI) induced a significantly enhanced cell viability inhibition (3 mM: 58.0±6.8%, Po0.05), when compared with either erlotinib or SU11274 treatment alone ( Figure 6A ). To further validate this combination dual TKI strategy, we also subjected the H1975 cells to pathway-specific siRNA knockdown of the MET and EGFR kinase signal paths, either alone or in combination, under serum-stimulated conditions ( Figure 6B ). Optimal downstream signalling inhibition (phospho-AKT and phospho-STAT3) and global phosphotyrosine (p-Tyr) cellular signalling inhibition were achieved through dual inhibition with siRNA knockdown of both MET and EGFR targets, when compared with single target knockdown. Taken together, these data provide support that cooperative enhanced inhibition using dual TKIs against MET and EGFR pathways may be an effective treatment strategy to inhibit lung cancer with intrinsic or acquired T790M-EGFR-mediated TKI resistance.
Finally, we also tested concurrent dual SU11274 plus erlotinib combinatorial treatment in our in vivo H1975-luc BLI xenograft , 15 min) and inhibited by MET inhibitor SU11274 (1 mM, 4 h) in vitro, and analysed with 7.5% SDS -PAGE and immunoblotting with the indicated antibodies as described in Materials and Methods. (B, C) Magnetic resonance imaging (MRI) and microPET molecular imaging studies of MET inhibition of H1975 in vivo xenograft. H1975 in vivo xenografts were established as above for treatment with either diluent control (N ¼ 2) or SU11274 (N ¼ 2). The nude mice with H1975 xenografts were subjected to MRI and microPET imaging as described in the Materials and Methods section at 0, and 24 h with the MET inhibitor SU11274 treatment or diluent control. (B) Examples of the transverse sections of high-resolution MRI images of the tumour xenografts at baseline between the two treatment groups were shown here for illustration (left). The MRI tumour volumes were analysed digitally with the calculated tumour volume changes at the indicated time intervals (0 and 24 h) plotted. Comparing with baseline, the control xenograft tumour volume increased by 105.1±8.3% at 24 h, whereas the SU11274-treated xenografts increased by 120.2±16.2% at 24 h. The MRI tumour volumes changes at 24 h post-treatment between the two groups were not statistically significant (*P ¼ 0.360). Error bar, s.e.m. Quantitative microPET radiotracer uptake of the H1975 tumour xenografts at 60 min of radiotracer tail-vein infusion in the animals' pretreatment baseline (0 h) and post-MET-TKI treatment at 24 h is shown graphically (right). N ¼ 2 in each treatment group: Control and SU11274. Error bar, s.e.m. Representative co-registered pictures of the microPET/MRI (low-resolution) images of each xenograft from the two treatment groups are shown in (C). SU11274 induced early tumour metabolic response, as early as 24-h post-TKI treatment, with statistically significant inhibition of glucose metabolism as evident in the decrease in microPET uptake signal intensity by 45% (P ¼ 0.0226) in SU11274-treated xenografts, when compared with diluent control. The degree of increase in the glucose uptake in the H1975 tumour xenograft in diluent control is also consistent with the average rate of the xenograft growth (increase of 50.8% BLI flux per day) as reflected in the bioluminescence imaging. growth assay ( Figure 6C ). Here, a suboptimal daily dose of SU11274 (50 mg per xenograft per day) was found to be partially effective in retarding the xenograft growth, when compared with either diluent control or erlotinib (100 mg kg À1 day À1 ) alone. Moreover, we found that combining SU11274 with erlotinib induced a complete tumour xenograft regression (0.12-fold BLI from baseline), evident within 2 weeks of dual inhibitor therapy. The difference seen with dual MET -EGFR-TKIs treatment is statistically significant when compared with either erlotinib alone (35.8-fold BLI increase, P ¼ 0.0006) or with SU11274 alone (12.2-fold, P ¼ 0.0003). These molecular imaging data were confirmed by xenograft H&E-stained histology examination ( Figure 6D ). In particular, the combined SU11274 plus erlotinib treatment resulted in substantial tumour necrosis.
DISCUSSION
At least half of the acquired resistance to EGFR-TKI in advanced NSCLC patients is thought to be mediated by the 'gatekeeper' mutation T790M in exon 20 of EGFR (Kobayashi et al, 2005a; Pao et al, 2005) . Many tumours with intrinsic resistance to erlotinib/ gefitinib were found to have wild-type EGFR and/or mutant KRAS. At present, no FDA-approved inhibitor drugs have been shown to be successful in overcoming T790M-mediated resistance clinically. Recent study suggested that T790M-EGFR-mediated resistance could even emerge from the irreversible EGFR/ERBB2 inhibitor HKI-272 treatment at maximally tolerated dosing, as it mediates resistance to low concentrations of the irreversible inhibitor (Godin-Heymann et al, 2008) . Alternative novel therapies to target lung cancer patients with intrinsic or acquired resistance to erlotinib are needed. MET has recently been affirmed to be an attractive anti-neoplastic therapeutic target (Corso et al, 2005; Peruzzi and Bottaro, 2006; Salgia, 2006) , including lung cancer (Christensen et al, , 2005 Ma et al, 2003a Ma et al, , b, 2005a Sattler et al, 2003) . MET was found overexpressed in up to 67% of lung adenocarcinomas in our previous study (Ma et al, 2005a) . Various targeted inhibitory strategies are being undertaken in drug development to antagonise MET/HGF signalling in human cancers, including small-molecule kinase inhibitors, antibodies to the ligand HGF, and receptor MET itself (Christensen et al, 2005; Martens et al, 2006; Peruzzi and Bottaro, 2006) . In this study, we identified that there is frequent co-expression of MET and EGFR in NSCLC cell lines. In the erlotinib-resistant H1975 cell line (L858R/T7980M-EGFR), MET is neither genomically amplified nor mutated. Yet, MET is activated in the cells, possessing both constitutive (serum/ligand-independent) and basal (serum-stimulated) receptor activation. Furthermore, MET also remains HGF ligand-sensitive. Owing to the unique intrinsic properties of MET regulating cellular 'invasive signalling', MET has been proposed as not merely playing a role in 'oncogene addiction' in a small subset of human cancers but can also play an essential role in 'oncogene expedience' by inducing an enhanced transformed tumour malignant 'fitness' in a much larger range of cancers leading to promotion of tumour progression (Comoglio et al, 2008) . And in the latter case, activated MET can intercept with various other oncogenic signals, including mutant-EGFR, in maintaining and enhancing the tumour invasive -progressive phenotype, thereby also allowing the opportunity for MET to be a therapeutic target even in late advanced metastatic disease. The MET inhibitor SU11274 was shown to promote apoptosis in H1975 cells, but was ineffective in the MET-negative/EGFR-negative H520 cells. SU11274 was previously characterised to be a selective, reversible ATP-competitive inhibitor of MET kinase (Sattler et al, 2003; Ma et al, 2005a) . Here, we show that SU11274 exhibited inhibitory efficacy in the EGFR-TKI-resistant H1975 cells both in vitro and In particular, it inhibited MET signalling, induced cellular apoptosis, and abrogated cytoskeletal functions (key controlling step in tumour invasion and metastasis) in vitro (Birchmeier et al, 2003) , and was effective in vivo, leading to cytoreduction of murine tumour xenografts of the T790M-EGFR expressing erlotinibresistant H1975 cells. Taken together, our study supports the hypothesis that MET may be targeted to circumvent T790M-EGFRmediated intrinsic or acquired resistance to EGFR-TKI (erlotinib) in lung cancer.
H1975 cells were tested further to provide a better understanding of the mechanism of dual MET -EGFR inhibition. A549 cell line was included as model in signalling studies for comparison with H1975 1, 3, 5, 6 ). Although receptor-specific TKI was able to inhibit the downstream signalling driven by the corresponding ligand stimulation, alternative ligand stimulation in the form of dual ligand stimulation rescued the inhibited downstream signals. Dual TKI SU11274 plus erlotinib inhibition was required to fully knockdown the dual ligand-stimulated downstream signal activation of AKT, ERK1/2, and STAT3 (lane 6). (E) MET inhibition with SU11274, in combination with EGFR inhibition using CL-387,785 (irreversible EGFR-TKI), induced cooperative downstream signalling inhibition in H1975 cells in vitro. Cells were cultured in starved media overnight, then treated with or without CL-387,785 and alone or in combination with MET inhibitor SU11274 as indicated. After 4 h of inhibitor treatment, cells were then stimulated with both EGF (100 ng ml
À1
) and HGF (50 ng ml À1 ) ligands as indicated for 15 min. Whole cell lysates were then collected for immunoblotting analysis. Similar to erlotinib, CL-387,785 further sensitised H1975 cells to SU11274 inhibition with enhanced cooperative inhibition of signalling pathways downstream of the two RTKs.
cells. A549 is an extensively studied lung cancer cell line and is known to have KRAS mutation but not any EGFR kinase domain mutations. In our in vitro signalling studies, we identified that there was signalling cross-activation between MET and EGFR in both A549 and H1975 cells. Nonetheless, the pattern of cross-activation appeared to be different between the two cell lines. In A549 cells, HGF brought about cooperative induction of p-EGFR [Y1068] in the presence of EGF, whereas in H1975 cells, EGF induced crossactivation of p-MET[Y1234/1235] by itself and further MET activation when combined with HGF in dual ligand stimulation. It is tempting to postulate that the different pattern of crossactivation observed in A549 and H1975 cells might be a result of the different EGFR kinase mutational status in the two cell lines, that is non-mutated in A549 but L858R/T790M in H1975. The mutant EGFR in H1975 evidently is capable of cross-activating MET in an EGF -ligand-dependent manner, indicating that MET could be 'downstream' of the mutant EGFR in H1975. Of interest, it has recently been shown that the MET receptor activating phosphorylation site was highly responsive to EGFRvIII levels in glioblastoma cells in vitro, suggesting downstream cross-activation of MET by mutant EGFRvIII .
L858R/T790M-EGFR mutations exist in H1975 cells in-cis (Pao et al, 2005) . The double mutations not only confer resistance to gefitinib/erlotinib but also result in markedly enhanced catalytic kinase and oncogenic activity (Mulloy et al, 2007) . Emerging evidence suggests that the T790M 'gatekeeper' mutation may exist in lung tumours before EGFR-TKI therapeutic selection (Bell et al, 2005; Godin-Heymann et al, 2007) , partly due to its enhanced oncogenicity, and accounts for the adverse clinical course and outcome in gefitinib/erlotinib-resistance lung cancers after a course of rapid TKI selection. Interestingly, we found that H1975 cells co-express EGFR and MET at high level, although without any MET genomic amplification, and were capable of serum-independent constitutive MET activation. Moreover, MET and EGFR engage in collaborative signalling cross-activation to transduce stronger and more durable downstream signals. A recent report utilised a mutant EGFR (deletion 19)-expressing NSCLC cell line HCC827, which is highly sensitive to gefitinib, an in vitro gefitinib-resistance long-term inhibition culture system to select for gefitinib-resistant cell subclones . Acquired MET amplification was identified to be a potential alternative mechanism to enable the mutant EGFR-expressing HCC827 to become secondarily resistant (HCC827-GR) without a T790M mutation. In the course of our study, Bean et al (2007) reported the presence of MET amplification that occurred independently with and without T790M-EGFR mutation in lung tumours. MET amplification in gastric cancer cell lines has recently been correlated with high sensitivity towards MET inhibitor (Smolen et al, 2006) . Interestingly, another recent report adopted a global phosphoproteomic approach using cell lines sensitive to gefitinib (HCC827) and sensitive to SU11274 (MKN45), and showed that besides p-EGFR inhibition, gefitinib also inhibited p-MET (that is indeed constitutively activated) in HCC827, but not vice versa (Guo et al, 2008) . In the case of SU11274, the MET inhibitor inhibited p-EGFR in MKN45 besides p-MET, but not vice versa (Guo et al, 2008) . Further studies to examine the signalling cross-talk between the EGFR and MET receptor pathways in the context of mutations and downstream signalling networking would be helpful in optimising combinational therapeutic strategies. Moreover, it would be useful to further investigate and catalogue the activating mechanisms of MET (such as activating mutations, transcriptional and protein overexpression), and their role in oncogenic signalling in the context of multiple receptor co-activation in lung cancer. Our report here demonstrates the efficacy of dual RTK targeted inhibition against MET (SU11274) and EGFR (erlotinib or CL-387,785) as a strategy to achieve optimised inhibition of cytoskeletal functions, cell viability, cellular signalling, and in vivo xenograft complete regression in T790M-EGFR-mediated erlotinib resistance. The concentrations of SU11274 used in our current study are consistent with previous results to be within the range of selectivity towards MET (Sattler et al, 2003; Ma et al, 2005a) . Finally, our dual siRNA knockdown experiment against MET and EGFR ( Figure 6B ) in H1975 cells provides further validation of this novel therapeutic approach. Dual inhibition may be of benefit over single target inhibition, especially in the context of serum and/or alternative ligand stimulation. This can be of clinical relevance considering that tumour cells often exist and adapt in vivo under a multitude of host stromal conditions during various stages of tumour progression, including serum starvation (e.g. in tumour core), serum-stimulation, and also potentially microenvironmentspecific ligand(s)-stimulation.
Dual TKI combinatorial approach may allow more effective target inhibition with a lower MET inhibitor concentration requirement, when compared with monotherapy alone, as suggested in our in vivo H1975-luc xenograft study. The ability to use lower drug concentrations than that in monotherapy would be beneficial and clinically relevant to minimise additive toxicity profiles of two inhibitor drugs of similar class used in combination. It is intriguing that we consistently observed a modest, but readily detectable degree of potentiated inhibition of MET phosphorylation by erlotinib, with and without SU11274, both in A549 and in H1975 cells. In addition, our siRNA-EGFR knockdown study in H1975 cells resulted in appreciable downregulation of p-MET[Y1234/1235], suggesting that the mutant EGFR in H1975 cells might signal into MET as a 'downstream' cross-talk collaborative signal partner ( Figure 6B ). It may account for some of the enhanced inhibitory effects seen in the dual TKI treatment. In our in vivo bioluminescence xenograft model, combined SU11274 -erlotinib inhibition remarkably induced complete H1975-luc tumour xenograft regression associated with histological features of massive tumour necrosis -apoptosis. We were initially intrigued that despite the lack of effective inhibition of EGFR phosphorylation (at pY1068) by erlotinib alone, the drug enhanced inhibitory efficacy both in vitro and in vivo in H1975 cells when combined with SU11274. Engelman et al (2007) recently reported that MET, when amplified genomically as in the setting of acquired EGFR-TKI resistance, can capture the ERBB3 signal control from EGFR. Our data here suggest that MET inhibition (SU11274) in H1975 cells had a modest but detectible negative effect on ERBB3 activation, and that dual SU11274/erlotinib inhibition cooperatively abrogated p-ERBB3 signal activation completely ( Figure 5B ). This might partially explain the observed role of erlotinib in the dual inhibitory strategy against the T790M-EGFR mutant cells, even though it is ineffective against p-EGFR itself. Further studies to dissect the interplay between MET and ERBB3 signal paths in lung cancer are warranted. Besides the possible effect of erlotinib upon MET activation per se, one might not rule out other potential off-target effects of erlotinib as contributing factors. Stegmaier et al (2005) first reported a previously unrecognised EGFR-independent mechanism of gefitinib in inducing the differentiation and inhibiting proliferation of EGFR-negative acute myeloid leukaemia cells at clinically achievable doses (Stegmaier et al, 2005) . More recently, erlotinib was also found to exhibit off-target antineoplastic effects in acute myeloid leukaemia and myelodysplastic syndrome, supporting the potential clinical therapeutic utility of these EGFR-TKIs in haematologic malignancies (Boehrer et al, 2007) . As erlotinib is currently the only clinically approved EGFR-TKI for lung cancer in the United States, discovery of its utility in combinatorial inhibitory approaches would be of potential clinical benefit. Combination strategy to target EGFR and MET has recently been reported to show promise in overcoming mutant-EGFRvIII-driven glioblastoma, although using a higher concentration range of MET inhibitor . Some success to overcome T790M-mutant EGFR resistance has been reported using irreversible EGFR/ERBB family inhibitors, such as CL-387,785 and HKI-272 (Kobayashi et al, 2005b; Wong, 2007) . Nonetheless, recent work in a L858R/T790M-EGFR transgenic mouse model suggests that the double mutant-EGFR responds only partially to HKI-272 alone (Li et al, 2007) , and enhanced inhibition was seen in combination with mammalian target of rapamycin inhibitor.
In conclusion, the present study identified that despite having no genomic MET alterations in H1975 cells, the MET -HGF signal path is functional and activated in this EGFR-TKI-resistant cell line that already expresses the oncogenic mutant EGFR (L858R/T790M) signal axis. There are also receptor cross-activation and signalling circuitry cross-talk between MET and EGFR, and MET inhibition has efficacy in vitro and in vivo in the erlotinib-resistant H1975 cells. Our results also implicate that combination treatment using a MET inhibitor plus a reversible or irreversible EGFR kinase inhibitor to achieve dual MET -EGFR inhibition may represent an alternative strategy to circumvent T790M-EGFR-mediated resistance in lung cancer. Importantly, erlotinib may still have clinical utility in this context of combined inhibition with MET inhibitor in EGFR-TKI-resistant lung cancer. As T790M-EGFR may play a role in both intrinsic and acquired EGFR-TKI resistance in lung cancer, it would be useful to test concurrent combinatorial MET -EGFR inhibitors in clinical trials on lung cancer patients refractory to erlotinib/gefitinib. Other emerging pan-ERBB class inhibitors, such as PF00299804, or EGFR-targeting dual/multitargeted inhibitors, such as lapatinib (EGFR/ERBB2 inhibitor) or ZD6474 (EGFR/VEGFR2 inhibitor), might also be candidates for combination with MET inhibitors. Whether a combined MET -EGFR inhibitory strategy as upfront treatment is superior to MET inhibition used only after EGFR-TKI monotherapy failure should be the subject of further investigation.
